Advertisement

Pfizer to cut 800 scientists

Pfizer will eliminate 5 to 8 percent of its global research staff this year, totaling about 800 people, according to a spokesperson for the company. Pfizer began one-on-one conversations today with colleagues getting the boot, with the majority of lay-offs happening in the next several months, company spokesperson Christopher Loder told The Scientist. Loder declined to provide details on which research divisions will be hit the hardest but emphasized that Pfizer is honing its research staff to

By | January 13, 2009

Pfizer will eliminate 5 to 8 percent of its global research staff this year, totaling about 800 people, according to a spokesperson for the company. Pfizer began one-on-one conversations today with colleagues getting the boot, with the majority of lay-offs happening in the next several months, company spokesperson Christopher Loder told The Scientist. Loder declined to provide details on which research divisions will be hit the hardest but emphasized that Pfizer is honing its research staff to six major areas of disease research: oncology, Alzheimer's, schizophrenia, pain, diabetes, and inflammation. "We do not make these decisions lightly," he said. "We are aware that this decision will affect a of number people, colleagues, and their family. We are committed to supporting our colleagues through this transition." Pfizer suffered last year from slumping sales of its blockbuster cholesterol drug Lipitor, thanks to the availability of a generic version. "This is probably not the end" of layoffs at Pfizer, linkurl:Erik Gordon,;http://www.bus.umich.edu/FacultyBios/FacultyBio.asp?id=000191546 a professor at the University of Michigan Business School and biopharmaceutical analyst, told linkurl:The New York Times.;http://www.nytimes.com/2009/01/14/business/14pfizer.html?_r=2&hp The pharmaceutical giant is not the only one cutting jobs and reorganizing priorities. Last October Merck announced that it would slash 7,200 jobs by 2011. In addition, Merck and Novartis both have recently revamped their research and development tactics.
**__Related stories:__***linkurl:Merck to cut jobs;http://www.the-scientist.com/blog/display/55103/
[22nd October 2008]*linkurl:New directions for drug discovery;http://www.the-scientist.com/blog/display/55274/
[9th December 2008]*linkurl:Pfizer embraces stem cells;http://www.the-scientist.com/blog/display/55051/
[24th September 2008]

Comments

Avatar of: Brandt Levitt

Brandt Levitt

Posts: 3

January 14, 2009

They manage these places into the ground and they layoff the workers like its their faults. Jerks
Avatar of: anonymous poster

anonymous poster

Posts: 1

January 14, 2009

\n\n\nWhy not the management personnel of Pfizer? They take major company decisions and they should be removed first. Pharmaceutical companies need best scientific minds.\n
Avatar of: Bob Hong

Bob Hong

Posts: 125

January 15, 2009

feel sorry or glad for the research scientists at Pfizer who were making far more than their academic peers, but at the higher risk of such fate when they work for private enterprises.

Follow The Scientist

icon-facebook icon-linkedin icon-twitter icon-vimeo icon-youtube
Advertisement

Stay Connected with The Scientist

  • icon-facebook The Scientist Magazine
  • icon-facebook The Scientist Careers
  • icon-facebook Neuroscience Research Techniques
  • icon-facebook Genetic Research Techniques
  • icon-facebook Cell Culture Techniques
  • icon-facebook Microbiology and Immunology
  • icon-facebook Cancer Research and Technology
  • icon-facebook Stem Cell and Regenerative Science
Advertisement
Advertisement
Mettler Toledo
Mettler Toledo
Life Technologies